Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079204382> ?p ?o ?g. }
- W2079204382 endingPage "2749" @default.
- W2079204382 startingPage "2739" @default.
- W2079204382 abstract "Chronic hepatitis C virus (HCV) infection can persist even in the presence of a broadly neutralizing antibody response. Various mechanisms that underpin viral persistence have been proposed, and one of the most recently proposed mechanisms is the presence of interfering antibodies that negate neutralizing responses. Specifically, it has been proposed that antibodies targeting broadly neutralizing epitopes located within a region of E2 encompassing residues 412 to 423 can be inhibited by nonneutralizing antibodies binding to a less conserved region encompassing residues 434 to 446. To investigate this phenomenon, we characterized the neutralizing and inhibitory effects of human-derived affinity-purified immunoglobulin fractions and murine monoclonal antibodies and show that antibodies to both regions neutralize HCV pseudoparticle (HCVpp) and cell culture-infectious virus (HCVcc) infection albeit with different breadths and potencies. Epitope mapping revealed the presence of overlapping but distinct epitopes in both regions, which may explain the observed differences in neutralizing phenotypes. Crucially, we failed to demonstrate any inhibition between these two groups of antibodies, suggesting that interference by nonneutralizing antibodies, at least for the region encompassing residues 434 to 446, does not provide a mechanism for HCV persistence in chronically infected individuals." @default.
- W2079204382 created "2016-06-24" @default.
- W2079204382 creator A5001910378 @default.
- W2079204382 creator A5022914731 @default.
- W2079204382 creator A5027895154 @default.
- W2079204382 creator A5036863708 @default.
- W2079204382 creator A5037749325 @default.
- W2079204382 creator A5048573821 @default.
- W2079204382 creator A5081606290 @default.
- W2079204382 date "2012-03-01" @default.
- W2079204382 modified "2023-09-23" @default.
- W2079204382 title "Naturally Occurring Antibodies That Recognize Linear Epitopes in the Amino Terminus of the Hepatitis C Virus E2 Protein Confer Noninterfering, Additive Neutralization" @default.
- W2079204382 cites W1902746983 @default.
- W2079204382 cites W1912626796 @default.
- W2079204382 cites W1963755147 @default.
- W2079204382 cites W1964573817 @default.
- W2079204382 cites W1967491261 @default.
- W2079204382 cites W1969654131 @default.
- W2079204382 cites W1980189090 @default.
- W2079204382 cites W1980843025 @default.
- W2079204382 cites W1993690048 @default.
- W2079204382 cites W2000782434 @default.
- W2079204382 cites W2000835793 @default.
- W2079204382 cites W2003579943 @default.
- W2079204382 cites W2004651002 @default.
- W2079204382 cites W2006538744 @default.
- W2079204382 cites W2008860633 @default.
- W2079204382 cites W2012420380 @default.
- W2079204382 cites W2015878390 @default.
- W2079204382 cites W2017359325 @default.
- W2079204382 cites W2021900004 @default.
- W2079204382 cites W2022077416 @default.
- W2079204382 cites W2030371794 @default.
- W2079204382 cites W2035508195 @default.
- W2079204382 cites W2042994480 @default.
- W2079204382 cites W2047619471 @default.
- W2079204382 cites W2049107903 @default.
- W2079204382 cites W2050502453 @default.
- W2079204382 cites W2051481258 @default.
- W2079204382 cites W2053536599 @default.
- W2079204382 cites W2058860357 @default.
- W2079204382 cites W2059774016 @default.
- W2079204382 cites W2066705292 @default.
- W2079204382 cites W2071904124 @default.
- W2079204382 cites W2072187355 @default.
- W2079204382 cites W2075147482 @default.
- W2079204382 cites W2077103006 @default.
- W2079204382 cites W2087924794 @default.
- W2079204382 cites W2090297731 @default.
- W2079204382 cites W2094254049 @default.
- W2079204382 cites W2097382368 @default.
- W2079204382 cites W2098821127 @default.
- W2079204382 cites W2099046838 @default.
- W2079204382 cites W2106399441 @default.
- W2079204382 cites W2107095788 @default.
- W2079204382 cites W2108463852 @default.
- W2079204382 cites W2110842901 @default.
- W2079204382 cites W2113300247 @default.
- W2079204382 cites W2119878965 @default.
- W2079204382 cites W2122043154 @default.
- W2079204382 cites W2129451072 @default.
- W2079204382 cites W2132046473 @default.
- W2079204382 cites W2132048270 @default.
- W2079204382 cites W2132108285 @default.
- W2079204382 cites W2141626800 @default.
- W2079204382 cites W2145254117 @default.
- W2079204382 cites W2147126871 @default.
- W2079204382 cites W2147679735 @default.
- W2079204382 cites W2149951088 @default.
- W2079204382 cites W2153923196 @default.
- W2079204382 cites W2167714763 @default.
- W2079204382 cites W2169035733 @default.
- W2079204382 cites W2169214521 @default.
- W2079204382 cites W2169460707 @default.
- W2079204382 cites W2172176008 @default.
- W2079204382 cites W2792087431 @default.
- W2079204382 cites W4252500291 @default.
- W2079204382 doi "https://doi.org/10.1128/jvi.06492-11" @default.
- W2079204382 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3302288" @default.
- W2079204382 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22171278" @default.
- W2079204382 hasPublicationYear "2012" @default.
- W2079204382 type Work @default.
- W2079204382 sameAs 2079204382 @default.
- W2079204382 citedByCount "59" @default.
- W2079204382 countsByYear W20792043822012 @default.
- W2079204382 countsByYear W20792043822013 @default.
- W2079204382 countsByYear W20792043822014 @default.
- W2079204382 countsByYear W20792043822015 @default.
- W2079204382 countsByYear W20792043822016 @default.
- W2079204382 countsByYear W20792043822017 @default.
- W2079204382 countsByYear W20792043822018 @default.
- W2079204382 countsByYear W20792043822020 @default.
- W2079204382 countsByYear W20792043822021 @default.
- W2079204382 countsByYear W20792043822022 @default.
- W2079204382 countsByYear W20792043822023 @default.
- W2079204382 crossrefType "journal-article" @default.
- W2079204382 hasAuthorship W2079204382A5001910378 @default.
- W2079204382 hasAuthorship W2079204382A5022914731 @default.